Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23 Nasopharyngeal Carcinoma 11 Squamous Cell Carcinoma of Head and Neck 9 Small Cell Lung Carcinoma 9 Uterine Cervical Neoplasms 7 Cholangiocarcinoma 6 Biliary Tract Neoplasms 6 Urinary Bladder Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Lung Neoplasms 4 Head and Neck Neoplasms 4 Stomach Neoplasms 3 Neoplasm Metastasis 3 Nasopharyngeal Neoplasms 3 Endometrial Neoplasms 3 Ovarian Neoplasms 2 Neoplasms 2 NSCLC 2 Esophageal Neoplasms 2 Breast Neoplasms 2 Unresectable Locally Advanced or Metastatic Solid Tumors 1 Triple Negative Breast Neoplasms 1 Tongue Squamous Cell Carcinoma 1 Thyroid Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Solid Tumor Cancer 1 Recurrence 1 Rare Tumour 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Rare Tumour × Cisplatin × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡